Last edition
News about "NSCLC"
Illumina, Labcorp Expand Partnership to Boost Access to Precision Oncology Testing
Illumina and Labcorp deepen collaboration to expand next-generation sequencing-based cancer testing, improve access to biomarker diagnostics, and accelerate development of precision oncology solutions.
NSCLC | 19/03/2026 | By News Bureau | 147
Immutep Limited will discontinue the Phase III TACTI-004 trial of eftilagimod alfa in first-line Non-Small Cell Lung Cancer after an interim analysis by the monitoring committee found the study unlikely to meet endpoints.
NSCLC | 16/03/2026 | By News Bureau
A multi-institutional study published in the Journal for ImmunoTherapy of Cancer finds that an AI-based imaging biomarker can predict immunotherapy outcomes and detect early treatment response in lung cancer patients.
NSCLC | 11/03/2026 | By News Bureau
Jiahui International Cancer Centre in Shanghai treats a US patient with advanced Non?Small Cell Lung Cancer using Ivonescimab, an experimental immunotherapy currently available only in China.
NSCLC | 09/03/2026 | By News Bureau
Novocure secures Japan insurance reimbursement for Optune Lua in advanced lung cancer treatment
Novocure receives reimbursement approval from Japan’s Ministry of Health, Labour and Welfare of Japan for Optune Lua, enabling insured access for advanced NSCLC patients using Tumour Treating Fields therapy.
NSCLC | 05/03/2026 | By News Bureau | 102
CStone Pharmaceuticals Secures UK MHRA Approval for Sugemalimab in Stage III NSCLC
The UK Medicines and Healthcare products Regulatory Agency grants a new indication for sugemalimab monotherapy in unresectable Stage III NSCLC, expanding its European footprint and global commercial reach.
NSCLC | 23/02/2026 | By News Bureau | 170
Simplified once-monthly schedule for RYBREVANT FASPRO matches bi-weekly efficacy, reduces clinic visits and maintains a strong safety profile.
NSCLC | 18/02/2026 | By News Bureau
Eisai, Nuvation Bio Collaborates to Expand Taletrectinib's Global Reach
The collaboration between Eisai and Nuvation to expand global development and commercialisation of taletrectinib for ROS1-positive non-small cell lung cancer.
NSCLC | 15/01/2026 | By News Bureau | 198
Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC
Lantern Pharma Inc. has secured regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.
NSCLC | 23/04/2024 | By Aishwarya | 319
Genentech Receives Approval from FDA for Alecensa
Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
NSCLC | 22/04/2024 | By Aishwarya | 679
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy